Chunfeng Yin

This inventor holds 10 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignees: Pfizer Corporation, Pfizer Products Inc., Nitto-Denko Corporation. Active years: 2008-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chunfeng Yin. Retrieved from https://idiyas.com/inventor/chunfeng-yin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 10

% Patents Active = 80.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 5.7

ph-index = 4

Forward Citations = 53(Granted Patents)

Company Filing History:

Nitto-Denko Corporation

patents

where one patent can have more than one assignee

Years Active: 2008-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11780853 - Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors (2023-10-10),

2. 11220518 - Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors (2022-01-11),

3. 10316045 - Substituted pyrrolo[3,4-c]pyrazoles as pkc kinase inhibitors (2019-06-11),

4. 9518060 - Substituted pyrrolo[3,4-c]pyrazoles as PKC kinase inhibitors (2016-12-13),

5. 9078926 - Polymer conjugates with a linker (2015-07-14),

6. 8999981 - [object Object] (2015-04-07),

7. 8877761 - N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors (2014-11-04),

8. 8183255 - N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors (2012-05-22),

9. 8114871 - 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives (2012-02-14),

10. 7468375 - Inhibitors of the HIV integrase enzyme (2008-12-23),

Title: The Innovative Contributions of Chunfeng Yin

Introduction

Chunfeng Yin is a prominent inventor based in San Diego, California, known for his significant contributions to the field of pharmaceutical sciences. With a total of 10 patents to his name, Yin has made remarkable strides in developing compounds that target various diseases.

Latest Patents

Among his latest patents, Chunfeng Yin has developed substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors. This invention relates to protein kinase C beta II inhibiting compounds of Formula (A). The compounds and pharmaceutically acceptable salts of Formulas A and B are designed to treat a range of conditions, including diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, Alzheimer's disease, and dermatological diseases. Additionally, these compounds may address viral diseases and inflammatory disorders, particularly those affecting the liver.

Career Highlights

Chunfeng Yin has had a distinguished career, working with leading pharmaceutical companies such as Pfizer Corporation and Pfizer Products Inc. His work has been instrumental in advancing therapeutic options for various health conditions.

Collaborations

Throughout his career, Chunfeng Yin has collaborated with notable colleagues, including Seiji Nukui and Hui Li. These partnerships have contributed to the successful development of innovative pharmaceutical solutions.

Conclusion

Chunfeng Yin's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a key innovator. His work continues to impact the treatment of numerous diseases, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.